Chronic Myelocytic Leukemia (CML) - Pipeline Insight, 2024

This “Chronic Myelomonocytic Leukaemia (CML) - Pipeline Insight, 2024,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Chronic Myelomonocytic Leukaemia (CML) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chronic Myelomonocytic Leukaemia (CML) Understanding

Chronic Myelomonocytic Leukaemia (CML): Overview

Chronic Myelomonocytic Leukaemia (CML) (CMML) is a form of leukaemia that is characterised by high numbers of white blood cells, called ‘monocytes’, in the blood and bone marrow. CMML is an uncommon blood cancer with features of two other types of blood cancer. Even though it has leukaemia as part of its name, the World Health Organisation (WHO) classifies CMML as a ‘mixed myelodysplastic (MDS) myeloproliferative neoplasm (MPN)’. MPN is a group of disorders of the bone marrow stem cells that produce excess numbers of one or more types of blood cells (red cells, white cells, or platelets). MDS is a group of diseases that affects, to a greater or lesser extent, the production of normal blood cells in the bone marrow.

Chronic Myelomonocytic Leukaemia (CML) - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Myelomonocytic Leukaemia (CML) pipeline landscape is provided which includes the disease overview and Chronic Myelomonocytic Leukaemia (CML) treatment guidelines. The assessment part of the report embraces, in depth Chronic Myelomonocytic Leukaemia (CML) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Myelomonocytic Leukaemia (CML) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Myelomonocytic Leukaemia (CML) R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Myelomonocytic Leukaemia (CML).

Chronic Myelomonocytic Leukaemia (CML) Emerging Drugs Chapters

This segment of the Chronic Myelomonocytic Leukaemia (CML) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Myelomonocytic Leukaemia (CML) Emerging Drugs

Sabatolimab: Novarits Oncology Sabatolimab (MBG 453) is an anti T-cell immunoglobulin and mucin domain 3 (anti-TIM3) monoclonal antibody that is being developed by Novartis Oncology. The drug is currently in phase III stage of development for the treatment of Chronic Myelomonocytic Leukaemia(CML).

Enasidenib: Servier Enasidenib (AG 221) is a small molecule, oral inhibitor of isocitrate dehydrogenase 2 (IDH2), being developed by Servier. The drug is currently in phase I stage of development for the treatment of Chronic Myelomonocytic Leukaemia(CML).

Chronic Myelomonocytic Leukaemia (CML): Therapeutic Assessment

This segment of the report provides insights about the different Chronic Myelomonocytic Leukaemia (CML) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Myelomonocytic Leukaemia (CML)

There are approx. 25+ key companies which are developing the therapies for Chronic Myelomonocytic Leukaemia (CML). The companies which have their Chronic Myelomonocytic Leukaemia (CML) drug candidates in the most advanced stage, i.e. phase III include, Novarits Oncology.

Phases

This report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Chronic Myelomonocytic Leukaemia (CML) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Myelomonocytic Leukaemia (CML): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Myelomonocytic Leukaemia (CML) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Myelomonocytic Leukaemia (CML) drugs.

Chronic Myelomonocytic Leukaemia (CML) Report Insights

• Chronic Myelomonocytic Leukaemia (CML) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Myelomonocytic Leukaemia (CML) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Myelomonocytic Leukaemia (CML) drugs?
• How many Chronic Myelomonocytic Leukaemia (CML) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Myelomonocytic Leukaemia (CML)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Myelomonocytic Leukaemia (CML) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Myelomonocytic Leukaemia (CML) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novarits Oncology
• Servier
• Eltrombopag
• Immune-Onc Therapeutics
• H3 Biomedicine
• Chroma Therapeutics
• Nerviano Medical Sciences
• Astex Pharmaceuticals
• Takeda Oncology
• Argenx
• Kura Oncology
• Incyte Corporation
• Genentech, Inc.
• Sensei Biotherapeutics
• Pfizer
• Bio Lite,Inc.
• Newave Pharmaceutical Inc
• Ellipses Pharma
• Eli Lilly and Company
• Aprea Therapeutics
• Treadwell Therapeutics
• Prelude Therapeutics
• Onconova Therapeutics
• Immune Pharmaceuticals
• Teva Pharmaceutical Industries

Key Products

• Sabatolimab
• Enasidenib
• IO 202
• H3B 8800
• Tefinostat
• NMS 03592088
• Guadecitabine
• Pevonedistat
• Cusatuzumab
• Tipifarnib
• Ruxolitinib
• Venetoclax
• SNS-301
• Cobimetinib
• Glasdegib
• BLEX 404
• LP-108
• Canakinumab
• EP0042
• LY3410738
• APR-246
• CFI-400945
• PRT543
• Rigosertib
• Histamine dihydrochloride injection
• Arsenic trioxide

This product will be delivered within 2 business days.